Mechanisms of Formation and Persistence of Active HIV Reservoirs
活性 HIV 病毒库的形成和持续机制
基本信息
- 批准号:8705776
- 负责人:
- 金额:$ 80.58万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-03-15 至 2019-02-28
- 项目状态:已结题
- 来源:
- 关键词:AcuteAddressAdultAnti-Retroviral AgentsAntigen TargetingAntigenic SpecificityAntigensApoptosisBackBiopsyBloodBronchoalveolar LavageCD4 Positive T LymphocytesCell CycleCell ProliferationCellsChromosomesChronicCytomegalovirusDNADataEarly treatmentEnrollmentEventGenesGoalsGut associated lymphoid tissueHIVHIV InfectionsHIV vaccineHIV-1Human Herpesvirus 4ImmunityIndividualInfantInfectionInterruptionIrrigationKineticsKnowledgeLeadLifeLinkLiquid substanceMethodsMyelogenousPatient CarePeripheral Blood Mononuclear CellPharmaceutical PreparationsPlasmaPopulationProductionProliferatingProteinsProvirus IntegrationProvirusesPublic HealthRNARelative (related person)ReportingResearchRestSimplexvirusSiteSorting - Cell MovementSpecimenStagingStudy SubjectT memory cellTargeted ToxinsTetanusTimeTissuesViralVirionVirusantiretroviral therapycohortexperiencefollow-upimprovedinfected B cellpandemic diseasepreventpublic health relevancesample collectionsite-specific integrationviral DNAviral RNA
项目摘要
ABSTRACT
We propose to address several important questions relevant to achieving a functional cure of HIV infection in
individuals on suppressive antiretroviral therapy (ART). Specifically, we will examine the timing and
mechanisms that establish the "active" or infectious reservoirs in primary human immunodeficiency virus type 1
(HIV-1) infection; identify the mechanisms by which active HIV reservoirs persist for many years under ART,
identify the cells that harbor active reservoirs, and; discern whether reservoirs in individuals initiating ART
during primary infection persist in antigen-specific cells and are thus amenable to activation with their target
antigens for destruction strategies. Our subject population derives from a unique and long standing cohort of
individuals enrolled while in the first few days to months of HIV infection, who went onto suppressive ART prior
to 4 months from the date of infection and have had intensive specimen collection during follow-up for up to
~14 years. One hundred and one subjects who initiated ART in Fiebig stages I-V, and remained on ART and
virologically suppressed for at least 2 years, form the primary set of subjects for study. Specimens from 4
additional subjects who started ART in chronic HIV infection and experienced a viral rebound when ART was
interrupted will be also be used to address one of our questions. We will quantify virus in plasma RNA, as total
viral DNA and as 2LTR circular unintegrated viral DNA in peripheral blood mononuclear cells (PBMC), and
examine the infectious capacity of proviral DNA in resting CD4+T cells. We will also determine the contribution
of proliferating HIV-infected cells, and the relationship between disruption of cellular genes regulating the cell
cycle by HIV integration into the chromosome, to the persistence of active reservoirs in blood and in specific
subpopulations in PBMC, bronchioalveolar lavage fluids and biopsies of gut-associated lymphoid tissues.
Additionally, we will determine whether the putative reservoirs we identify allow HIV to remain active by virtue
of inadequate intracellular levels of antiretroviral drugs. Our specific aims are to determine: 1) The mechanisms
and kinetics of establishment of active HIV reservoirs; 2) the relative contributions of (A) proliferating HIV-
infected cells, and (B) low-level viral replication to the persistence of active reservoirs during ART, and; 3) the
proportion of HIV reservoir cells composed of virus-specific CD4+T cells.
摘要
我们建议解决与实现艾滋病毒感染的功能性治愈有关的几个重要问题
接受抑制性抗逆转录病毒治疗(ART)的个人。具体地说,我们将研究时间和
在原发人类免疫缺陷病毒1型中建立“活性”或感染性储存库的机制
(HIV-1)感染;根据ART确定活跃的艾滋病毒宿主持续多年的机制;
识别拥有活跃储集层的细胞,并识别储集层是否存在于发起ART的个体中
在初次感染期间,持续存在抗原特异的细胞,因此容易与目标细胞一起激活
用于销毁战略的抗原。我们的受试者群体来自一个独特的和长期的队列
在HIV感染的最初几天到几个月内登记的个人,他们之前接受了抑制疗法
从感染之日起至4个月,并在随访期间进行密集的样本采集,最高可达
~14年。101名受试者在FieBig I-V阶段启动ART,并继续接受ART和
病毒学抑制至少2年,构成主要研究对象。标本来自4个
在慢性HIV感染中开始抗逆转录病毒治疗并在接受抗逆转录病毒治疗时经历病毒反弹的其他受试者
中断也将被用来回答我们的一个问题。我们将对血浆RNA中的病毒进行量化,
外周血单个核细胞(PBMC)中的病毒DNA和AS 2ltR环状未整合病毒DNA,以及
检测前病毒DNA在静息CD4+T细胞中的感染能力。我们还将确定捐款
HIV感染细胞的增殖,以及调控细胞的细胞基因中断之间的关系
周期通过HIV整合到染色体中,使血液中的活性蓄水池持续存在,并在特定情况下
PBMC、细支气管肺泡灌洗液和肠道相关淋巴组织活检中的亚群。
此外,我们将确定我们确定的假定宿主是否允许艾滋病毒凭借其自身的优势保持活跃
细胞内抗逆转录病毒药物水平不足。我们的具体目标是确定:1)机制
和建立活跃的艾滋病毒储存库的动力学;2)(A)增殖的艾滋病毒-
感染细胞,以及(B)低水平的病毒复制,以维持ART期间活跃的水库,以及;3)
HIV蓄积细胞中由病毒特异性的CD4+T细胞组成的比例。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JAMES Ivan MULLINS其他文献
JAMES Ivan MULLINS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JAMES Ivan MULLINS', 18)}}的其他基金
Ex Vivo Detection and Analysis of Non-inducible Latent HIV
非诱导性潜伏 HIV 的离体检测和分析
- 批准号:
9046237 - 财政年份:2015
- 资助金额:
$ 80.58万 - 项目类别:
Ex Vivo Detection and Analysis of Non-inducible Latent HIV
非诱导性潜伏 HIV 的离体检测和分析
- 批准号:
9187886 - 财政年份:2015
- 资助金额:
$ 80.58万 - 项目类别:
Mechanisms of Formation and Persistence of Active HIV Reservoirs
活跃HIV病毒库的形成和持续机制
- 批准号:
9229518 - 财政年份:2014
- 资助金额:
$ 80.58万 - 项目类别:
IMMUNOLOGICAL AND VIROLOGICAL EVENTS IN EARLY HIV INFECTION
HIV 感染早期的免疫学和病毒学事件
- 批准号:
7842962 - 财政年份:2010
- 资助金额:
$ 80.58万 - 项目类别:
Management and Retrieval of Multidisciplinary HIV Research Data
多学科 HIV 研究数据的管理和检索
- 批准号:
8019466 - 财政年份:2010
- 资助金额:
$ 80.58万 - 项目类别:
IMMUNOLOGICAL AND VIROLOGICAL EVENTS IN EARLY HIV INFECTION
HIV 感染早期的免疫学和病毒学事件
- 批准号:
8508162 - 财政年份:2010
- 资助金额:
$ 80.58万 - 项目类别:
IMMUNOLOGICAL AND VIROLOGICAL EVENTS IN EARLY HIV INFECTION
HIV 感染早期的免疫学和病毒学事件
- 批准号:
8691648 - 财政年份:2010
- 资助金额:
$ 80.58万 - 项目类别:
Management and Retrieval of Multidisciplinary HIV Research Data
多学科 HIV 研究数据的管理和检索
- 批准号:
7840648 - 财政年份:2010
- 资助金额:
$ 80.58万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 80.58万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 80.58万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 80.58万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 80.58万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 80.58万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 80.58万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 80.58万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 80.58万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 80.58万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 80.58万 - 项目类别:
Research Grant














{{item.name}}会员




